Drivers Of Crizotinib Resistance In Alk(+) Alcl
BLOOD（2020）
摘要
In this issue of Blood, Prokoph et al(1) seek to identify mechanisms by which ALK(+) anaplastic large cell lymphoma (ALCL) cells develop resistance to the ALK inhibitor crizotinib. Their findings implicate a novel and potentially targetable interleukin-10 (IL-10) receptor-dependent autocrine loop that bypasses ALK signaling.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要